Etomoxir|cas 828934-41-4|DC Chemicals|Price|Buy

Cas No.:	828934-41-4
Chemical Name:	(2R)-2-[6-(4-chlorophenoxy)hexyl]-2-oxiranecarboxylic acid monosodium salt
Synonyms:	Etomoxir sodium; B 807-54; B807-54; B-807-54; B 80754; B80754; B-80754;
SMILES:	[Na+].O1C[C@@]1(CCCCCCOC1=CC=C(Cl)C=C1)C([O-])=O
Formula:	C₁₅H₁₈ClNaO₄
M.Wt:	320.7448
Sotrage:	2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO

Description:	(R)-Etomoxir sodium salt is the R-form of Etomoxir sodium salt, acts as an inhibitorof carnitine palmitoyltransferase I (CPT-I), and inhibits palmitate β-oxidation in human, rat and guinea pig.
In Vitro:	(R)-Etomoxir sodium salt is the R-form of Etomoxir sodium salt, acts as an inhibitorof carnitine palmitoyltransferase I (CPT-I), and inhibits palmitate β-oxidation in human, rat and guinea pig[1].

Cat. No.	Product name	Field of application
DC77017	9(10)-Nitrooleate	9(10)-Nitrooleate（NOA）is an endogenous nitrated fatty acid that functions as a highly efficient bioactive molecule. Its primary role is the specific inhibition of the STING protein, a key inflammatory signaling sensor within cells. When STING is aberrantly activated, it can trigger a severe inflammatory response, leading to cellular damage.Mechanistically, NOA acts as an electrophile, capable of covalently modifying specific cysteine residues on the STING protein, thereby effectively blocking its ability to activate downstream signaling pathways. This inhibitory action establishes NOA as a potent endogenous anti-inflammatory agent. In practical application, loading NOA into delivery systems, such as lipid nanoparticles, equips them with an intrinsic "molecular fire extinguisher." It significantly mitigates the acute inflammatory response triggered by delivered cargo, effectively transforming otherwise toxic delivery vehicles into safe platforms. The core value of NOA lies in its ability to provide exceptional safety without compromising the functional expression of therapeutic payloads, offering a crucial safeguard for achieving long-term treatments.
DC9602	Balaglitazone	Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.
DC7412	R(+)-Etomoxir (sodium salt)	A PPARα agonist and an irreversible CPT-1 inhibitor.
DC1034	WY14643 (Pirinixic Acid)	WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with ED50 of 1.5 μM.
DC10700	Seladelpar	Seladelpar is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist.
DC12034	MA-0204	MA-0204 is a potent, selective PPARδ modulator with good pharmacokinetic properties.
DC2079	GW-9662	GW9662 is a selective PPAR antagonist, inhibiting PPARγ, PPARα and PPARδ with IC50 of 3.3 nM, 32 nM and 2 μM, respectively.
DC4233	GW501516	GW501516 is the most selective and potent PPARβ (EC50=1.1nM) agonist that has been demonstrated to be 1,000-fold more selective in comparison to existing subtypes.
DC9904	GW0742	GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
DC2078	GW-7647	GW 7647 is a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ.

R(+)-Etomoxir (sodium salt)